Publications
Schmidt B, Ashlock B, Neipel F, Levy JA. Potential screening assay for undetectable viruses on the basis of their capacity to induce alpha interferon production. Journal of clinical microbiology. 2004. PMID: 15365027
Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clinical prostate cancer. 2004. PMID: 15479496
Venook AP. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition. Journal of the National Comprehensive Cancer Network : JNCCN. 2004. PMID: 19780248
Venook AP. Key research issues in the management of hepatocellular carcinoma. Cancer chemotherapy and pharmacology. 2004. PMID: 15309518
Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15289492
Gudmundsdottir K, Ashworth A. BRCA2 in meiosis: turning over a new leaf. Trends in cell biology. 2004. PMID: 15308204
Logan AC, Haas DL, Kafri T, Kohn DB. Integrated self-inactivating lentiviral vectors produce full-length genomic transcripts competent for encapsidation and integration. Journal of virology. 2004. PMID: 15280451
Naing A, Messina JL, Vrionis FR, Daud AI. Uncommon manifestations of common malignancies: case 3. Malignant melanoma arising from a spinal nerve root. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004. PMID: 15284274
Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004. PMID: 15302462
Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. Development of ligand-targeted liposomes for cancer therapy. Expert opinion on therapeutic targets. 2004. PMID: 15268628
Martins SL, St John LS, Champlin RE, Wieder ED, McMannis J, Molldrem JJ, Komanduri KV. Functional assessment and specific depletion of alloreactive human T cells using flow cytometry. Blood. 2004. PMID: 15284108
Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (New York, N.Y.). 2004. PMID: 15256671
J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004. PMID:
J. L. Rubenstein, A. Shen, L. Abrey, D. Combs, C. Haqq, L. Damon, J. O'Brien, P. O'Connor, M. Prados, M. Shuman. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004. PMID:
Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004. PMID: 15221993
Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 15217939
Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochimica et biophysica acta. 2004. PMID: 15172699
Mizenina OA, Moasser MM. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell cycle (Georgetown, Tex.). 2004. PMID: 15136770
Locher CP, Witt SA, Ashlock BM, Polacino P, Hu SL, Shiboski S, Schmidt AM, Agy MB, Anderson DM, Staprans SI, zur Megede J, Levy JA. Human immunodeficiency virus type 2 DNA vaccine provides partial protection from acute baboon infection. Vaccine. 2004. PMID: 15149785
Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004. PMID: 15173097